Related Experiment Videos
Efficacy of itraconazole in blastomycosis in a murine model and comparison with ketoconazole
Mycoses
|January 1, 1989
Abstract:
Mice were infected intranasally with B. dermatitidis yeasts, and after infection treated orally. Itraconazole 50-150 mg/kg/day was protective (prolonged survival) against lethal infection, although the infection was not sterilized. Itraconazole was approximately 3 times as potent as ketoconazole. These results suggest advantages for itraconazole therapy clinically.
Insights
Itraconazole prolonged survival in mice infected with Blastomyces dermatitidis, demonstrating significant antifungal activity. While not sterilizing the infection, it showed superior potency compared to ketoconazole for potential clinical use.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Blastomyces dermatitidis (B. dermatitidis) is a fungal pathogen causing blastomycosis.
- Antifungal therapies are crucial for managing B. dermatitidis infections.
Purpose of the Study:
- To evaluate the efficacy of itraconazole in a murine model of B. dermatitidis infection.
- To compare the potency of itraconazole with ketoconazole.
Main Methods:
- Mice were infected intranasally with B. dermatitidis.
- Post-infection treatment with oral itraconazole (50-150 mg/kg/day) or ketoconazole was administered.
Main Results:
- Itraconazole treatment significantly prolonged survival in infected mice.
- Complete sterilization of the infection was not achieved with itraconazole.
- Itraconazole demonstrated approximately three times the potency of ketoconazole.
Conclusions:
- Itraconazole exhibits protective effects against lethal B. dermatitidis infection in mice.
- Itraconazole shows a favorable potency profile compared to ketoconazole.
- These findings suggest potential clinical advantages for itraconazole in treating blastomycosis.